Background: Proton pump inhibitors (PPIs) are used to prevent gastrointestinal hemorrhage in patients with coronary treatment undergoing dual antiplatelet therapy (DAPT).
Methods: A systematic review was performed to compare the outcomes between DAPT and DAPT + PPI in acute coronary syndrome (ACS) patients or patients who took percutaneous coronary intervention (PCI) with coronary stent implantation (PCI patients), and to estimate, for the first time, the sample size needed for reliable results via trial sequential analysis (TSA). The PubMed, EMBASE, the Cochrane Library and Web of Science databases were searched for articles authored from the onset until November 1, 2022, for randomized controlled trials (RCTs) comparing outcomes in ACS or PCI patients who undertook DAPT or DAPT + PPI. The primary outcomes were the incidence rate of gastrointestinal events and major adverse cardiovascular events (MACEs).
Results: The initial web search retrieved 786 literature references. Eventually, eight articles published between 2009 and 2020 were incorporated into the systematic review and meta-analysis. The combined results established a non-significant variation in MACEs incidences between the DAPT group and DAPT + PPI group [risk ratio (RR) = 0.93, 95% confidence interval (CI) = 0.81-1.06, = 0.27, = 0%]; conversely, the incidence of gastrointestinal events was significantly decreased in the DAPT + PPI group in comparison with the DAPT group (RR = 0.33, 95% CI = 0.24-0.45, 0.00001, = 0%). TSA of MACEs and gastrointestinal events revealed that meta-analysis included adequate trials (required sample size = 6874) in the pool to achieve 80% study power.
Conclusions: Based on our results, DAPT + PPI can significantly reduce gastrointestinal outcomes without affecting cardiovascular outcomes in PCI and ACS patients compared to DAPT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266793 | PMC |
| http://dx.doi.org/10.31083/j.rcm2408230 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Appropriateness of Antiplatelet Therapy and Proton Pump Inhibitor Prescribing in End-Stage Kidney Disease: A Retrospective Quality Investigation Study.
Can J Kidney Health Dis
January 2025
Division of Nephrology, Department of Medicine, Ottawa Hospital, University of Ottawa, ON, Canada.
Background: Patients with end-stage kidney disease (ESKD) have high rates of gastrointestinal bleeding due to several risk factors including platelet dysfunction, comorbid illness, and use of antiplatelet medications. Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding and are recommended for high-risk patients such as those prescribed dual antiplatelet therapy (DAPT). Whether inappropriate duration of DAPT therapy and/or lack of appropriate PPI use contribute to the known elevated risk of gastrointestinal bleeding in hemodialysis patients is not known.
View Article and Find Full Text PDFSystematic Review and Meta-Analysis: Role of Proton Pump Inhibitors in Prevention of Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy.
Am J Ther
December 2024
Division of Gastroenterology, Thomas Jefferson University Hospital, Philadelphia, PA.
Article Synopsis
- Dual antiplatelet therapy (DAPT) combined with proton pump inhibitors (PPI) can significantly reduce the risk of upper gastrointestinal bleeding (UGIB) in patients with acute coronary syndrome (ACS) compared to DAPT alone.
- A meta-analysis of seven randomized controlled trials involving 6708 patients showed a marked decrease in UGIB rates and all-cause mortality when PPI was added, with no negative impact on major cardiovascular events.
- Specifically, the PPI + DAPT group had a risk ratio of 0.39 for UGIB and 0.46 for mortality, indicating substantial benefits from this combination treatment.
The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study.
J Pharm Health Care Sci
November 2024
Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan.
Objective: Dual-antiplatelet therapy (DAPT) and proton pump inhibitor (PPI) are frequently prescribed after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) placement. However, studies that evaluate the optimal PPI when used as primary prevention in patients without a history of peptic ulcer disease or upper gastrointestinal bleeding (UGIB), particularly in the context of DAPT involving prasugrel, are lacking. This study aimed to assess the efficacy and safety of PPI use in preventing UGIB in this patient population.
View Article and Find Full Text PDFClinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians.
Expert Rev Cardiovasc Ther
September 2024
Cardiology Division, NYU School of Medicine, NYU Langone Health, New York, NY, USA.
Introduction: Patients on systemic oral anticoagulation with vitamin K antagonists (VKA) or non-vitamin K oral anticoagulants (NOAC) often require triple therapy following percutaneous coronary intervention, substantially increasing the risk of bleeding. Gastroprotective agents like proton pump inhibitors (PPI) are often employed to mitigate this risk, despite potential competitive inhibition between P2Y12-receptor inhibitors, NOACs, and VKAs. While the interactions and clinical outcomes of PPIs and DAPT have been frequently explored in literature, not many studies have evaluated the same outcomes for triple therapy.
View Article and Find Full Text PDFImpact of proton pump inhibitor use on clinical outcomes in East Asian patients receiving clopidogrel following drug-eluting stent implantation.
BMC Med
August 2024
Department of Cardiology, Korea University Anam Hospital, Korea University College of Medicine, Cardiovascular Center 73, Goryeodae-Ro, Seongbuk-Gu, Seoul, 02841, Republic of Korea.
Article Synopsis
- The study examined the effects of proton pump inhibitors (PPIs) on patients who underwent percutaneous coronary intervention (PCI) while taking clopidogrel for antiplatelet therapy, particularly focusing on their clinical outcomes and PRU levels.
- Among 13,160 patients, those using PPIs had higher PRU levels but did not show a significant increase in serious cardiovascular events when compared to non-users, with primary outcomes occurring in a similar proportion.
- However, for patients carrying certain genetic variations (CYP2C19 loss-of-function alleles), PPI use was associated with an increased risk of adverse outcomes, highlighting complex interactions between medication and genetics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!